Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Par Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Ethacrynate Sodium for Injection, the first generic version of Aton Pharma’s Sodium Edecrin.
Sodium Edecrin is loop diuretic indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required, such as in acute pulmonary edema, when gastrointestinal absorption is impaired, or when oral medication is not practicable.
RELATED: HCTZ Bottles Recalled After Discovery of Blood Thinner Tablet
Par Pharmaceuticals has begun shipping Ethacrynate Sodium for Injection, which is packaged in cartons of one 50mg single-dose vial.
For more information visit ParPharm.com.
Related Content
